Tricida to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Tricida, Inc. (Nasdaq: TCDA) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 12:50 pm PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tricida, Inc. (Nasdaq: TCDA) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 12:50 pm PT. CEO Gerrit Klaerner will discuss the company's initiatives and recent developments.
A live webcast of the event will be available on the Tricida website, with an archive accessible post-event. The company is focused on developing veverimer, a novel treatment for metabolic acidosis linked to chronic kidney disease. This condition affects around three million CKD patients in the U.S., with no existing FDA-approved therapies.
Details
News Market Reaction – TCDA
The recorded move for TCDA in the trading session of this news was -2.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET. Gerrit Klaerner, Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives.
A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow chronic kidney disease (CKD) progression in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. There are no FDA-approved treatments for chronic metabolic acidosis. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit Tricida.com.
Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com
Source: Tricida, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.